Harbin Gloria Pharmaceuticals Co (SZSE:002437) ROCE % : 16.13% (As of Mar. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Harbin Gloria Pharmaceuticals Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Harbin Gloria Pharmaceuticals Co's annualized ROCE % for the quarter that ended in Mar. 2024 was 16.13%.

Harbin Gloria Pharmaceuticals Co ROCE % Historical Data

The historical data trend for Harbin Gloria Pharmaceuticals Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harbin Gloria Pharmaceuticals Co ROCE % Chart

Harbin Gloria Pharmaceuticals Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-68.70

36.03

7.87

-10.71

12.62

Harbin Gloria Pharmaceuticals Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															10.74	6.96	47.69	-16.60	16.13

Harbin Gloria Pharmaceuticals Co ROCE % Calculation

Harbin Gloria Pharmaceuticals Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	219.432	/	( ( (4074.186 - 2336.31)	+	(3152.45 - 1412.228) )	/ 2 )
	=	219.432	/	( (1737.876	+	1740.222)	/ 2 )
	=	219.432	/	1739.049
	=	12.62 %

Harbin Gloria Pharmaceuticals Co's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	294.612	/	( ( (3152.45 - 1412.228)	+	(3079.865 - 1168.201) )	/ 2 )
	=	294.612	/	( ( 1740.222	+	1911.664 )	/ 2 )
	=	294.612	/	1825.943
	=	16.13 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Harbin Gloria Pharmaceuticals Co (SZSE:002437) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Harbin Gloria Pharmaceuticals Co ROCE % Related Terms

Thank you for viewing the detailed overview of Harbin Gloria Pharmaceuticals Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Harbin Gloria Pharmaceuticals Co (SZSE:002437) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Harbin Gloria Pharmaceuticals Co Ltd (SZSE:002437) » Definitions » ROCE %

Traded in Other Exchanges

N/A

Address

Beijing Road No 29, Harbin Economic and Technological Development Zone, Harbin, CHN, 150025

Website

http://www.gloria.cc

Harbin Gloria Pharmaceuticals Co Ltd is a tech biopharmaceutical enterprise. It is engaged in the research, development, production, and sale of pharmaceutical products primarily in China. The company offers cardiovascular drugs; cardiac cerebrovascular medication; vitamins and minerals; urinary tract drugs; urinary system medication; anti-tumor medication; endocrine system drugs; anti-infective drugs; digestive system medication; respiratory medication; and other medications.

Harbin Gloria Pharmaceuticals Co (SZSE:002437) Headlines

No Headlines